NASDAQ:OKYO

OKYO Pharma (OKYO) Stock Price, News & Analysis

OKYO Pharma logo
$1.07 -0.09 (-7.76%)
Closing price 11/20/2026 03:57 PM Eastern
Extended Trading
$1.09 +0.02 (+2.06%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About OKYO Pharma Stock (NASDAQ:OKYO)

Advanced

Key Stats

Today's Range
$1.04
▼
$1.25
50-Day Range
$1.07
▼
$1.54
52-Week Range
$1.00
▼
$3.20
Volume
76,392 shs
Average Volume
304,227 shs
Market Capitalization
$56.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67
Consensus Rating
Moderate Buy

Company Overview

OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and ocular pain. Its research focuses on therapies intended to reduce inflammation and improve symptoms affecting the eye.

The company’s lead candidate, urcosimod (OK-101), is a topical eye-drop treatment being developed for dry eye disease. It is designed to act on ChemR23, a receptor involved in regulating inflammation. OKYO has also investigated the candidate’s potential for treating neuropathic corneal pain.

AI Generated. May Contain Errors.

OKYO Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

OKYO MarketRank™: 
2.571328671325 of 5 stars

OKYO Pharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 441st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OKYO Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    OKYO Pharma has a consensus price target of $5.67, representing about 429.6% upside from its current price of $1.07.

  • Amount of Analyst Coverage

    OKYO Pharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about OKYO Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for OKYO Pharma are expected to decrease in the coming year, from ($0.13) to ($0.15) per share.

  • Price to Book Value per Share Ratio

    OKYO Pharma has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about OKYO Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.15% of the float of OKYO Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    OKYO Pharma has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in OKYO Pharma has recently decreased by 40.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    OKYO Pharma does not currently pay a dividend.

  • Dividend Growth

    OKYO Pharma does not have a long track record of dividend growth.

    • Insider Buying vs. Insider Selling

      In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      2.97% of the stock of OKYO Pharma is held by institutions.

    • Read more about OKYO Pharma's insider trading history.
    Receive OKYO Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    OKYO Stock News Headlines

    432 miles southeast of Washington, DC…
    Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip maker for nearly four decades, including AMD, Intel, NVIDIA, Samsung and Taiwan Semiconductor. Washington is set to declare it a national strategic resource and ban its export. Apple, NVIDIA and Amazon have committed over $2 trillion, and Morgan Stanley estimates a $10 trillion economic boom. One small U.S. mining company sits at the center of it.tc pixel
    See More Headlines

    OKYO Stock Analysis - Frequently Asked Questions

    OKYO Pharma's stock was trading at $2.07 at the beginning of the year. Since then, OKYO shares have decreased by 48.3% and is now trading at $1.07.

    OKYO Pharma (OKYO) raised $2 million in an IPO on Tuesday, May 17th 2022. The company issued 625,000 shares at $4.00 per share.

    Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Energy Transfer (ET), Pfizer (PFE), Denison Mine (DNN), Aurora Cannabis (ACB), Atlas Lithium (ATLX), Bitfarms (BITF) and Celsius (CELH).

    Company Calendar

    Today
    11/21/2026
    Next Earnings (Estimated)
    12/02/2026
    Fiscal Year End
    3/31/2027

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Biotechnology
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:OKYO
    CIK
    1849296
    Fax
    N/A
    Employees
    5
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $7.00
    Low Price Target
    $5.00
    Potential Upside/Downside
    +429.6%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    4 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    2.43
    Quick Ratio
    2.43

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.30 per share
    Price / Book
    3.57

    Miscellaneous

    Outstanding Shares
    52,480,000
    Free Float
    31,247,000
    Market Cap
    $56.15 million
    Optionable
    Not Optionable
    Beta
    0.02
    The 7 Hottest IPO Stories of 2026 Cover

    MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

    Get This Free Report

    This page (NASDAQ:OKYO) was last updated on 11/20/2026 by MarketBeat.com Staff.
    From Our Partners